This is paid content, to view it, log in or register as an irregular.
Monthly newsletter on biotech stocks with weekly updates.
Monthly newsletter on biotech stocks with weekly updates.
Focuses on companies with hot new technologies, including biotech and technology stocks. Formerly run by Patrick Cox, who moved on to launch Transformational Technology Alert, a similar letter for Mauldin Economics.
Healthcare-focused newsletter, recommends stocks primarily of emerging device and biotech companies.
Monthly newsletter highlighting technology and biotech stocks.
Focuses on small, potentially explosive growth companies, mostly in mining, tech and biotech. Formerly run by Rob Fannon.
Recommends trades (long and short) based on clinical trials, particularly for smaller pharmaceutical and biotech companies.
Limited-circulation biotech-focused newsletter.
Biotech/Emerging Tech Newsletter launched by Patrick Cox in second half of 2013, similar to the early-stage-tech newsletter Breakthrough Technology Alert that he ran for Agora for many years. Often recommends extremely small and speculative stocks.
Biotech-focused newsletter from Lichtenfeld, who previously edited the similar-sounding Access Group letters for White Cap Research.
Biotech-focused newsletter from the UK.
Recommends 6-8 small and microcap stocks annually, mostly in biotech, with weekly updates and conference calls with management of the companies they pick.
Biotech stock picking service.
This discussion came about as the result of the GS thread ”This Tiny, Unknown Biotech is About to Unleash Its ‘Holy Grail’ Drug” It is hoped that all/any that can throw light, can brainstorm here and feedback consensus to the thread. Good work Guys. my best Alan Harris.
Yesterday I promised to follow up on Louis Navellier’s biotech picks — these are three stocks teased and hinted at in the latest promo for his Emerging Growth newsletter. The first one, covered yesterday, was a Chinese vaccine company called Sinovac (SVA) — no stranger to the world of Gumshoe, but not a favorite of […]
Louis Navellier likely had a good year last year, since the kinds of stocks he typically likes did very well (generally growth stocks, those with rapid earnings growth that beat estimates and grow at increasing rates … and often look expensive, with high PEs) — and he’s out now with a new ad about biotech […]
Hi I’m Bob and new to this forum. I receive many emails as I’m sure you all do regarding miracle new discoveries and huge up potential gains that are coming. Agora Financial sent me this teaser today, not sure if this was laready covered and what the comments were as well as the symbol. Many […]
The phrase “Alzheimer’s Disease” sets off an almost pavlovian response among investors … we all know that Alzheimer’s is probably the least-understood major disease, and affects a spectacularly huge number of people, and even those who don’t get beyond fifth grade math can do the calculations: more than five million Americans have the disease, and […]
[Ed note: Following is another installment from our favorite medical scribe, "Doc Gumshoe" (no, he's not a doctor). We feature Michael's commentary every couple weeks or so, and his thoughts and words are his own. "Doc" doesn't pick stocks, but FDA decisions are a huge driver of investment success for pharmaceutical and biotech companies and […]
We’re well on our way to piling another foot of snow here atop Gumshoe Mountain, so I’ll keep today’s missive brief — there’s sledding to do, after all, and little Gumshoes out of school and craving amusement. I was skimming through a recent teaser pitch by Andy Obermueller for his Game-Changing Stocks letter, and it’s […]
A couple days ago we started getting a deluge of new queries from subscribers about something called “blue blood” — teasing a company that was about to sign contracts with major pharmaceutical companies, and which had a “lockdown” on a secret “blue blood” protein that will cure cancer. I was a little baffled at first, […]
[Ed note: This article was originally published in June, 2013 when the shares of the stock teased, Alnylam (ALNY) were around $30 and the Oxford Club was saying that the first person to live to 1,000 is already alive ... now they're touting it as the "The Tiny Company About to Go 'Public' With True […]
What’s this all about? I was in Intuitive Surgical and got out way too soon – don’t want to miss another one like that.
Can someone please explain the different technologies being developed by companies developing new vaccines( e.g. INO) and the pros and cons and potential of each. Thanks! Barry
Travis: At age 75 I’ve stopped trying to figure out anything more complicated than where I left my glasses. So could you shed a bit of light [or dark] on this subject? Thanks John A.
Does anyone have an opinion/any info on OPKO health (NYSE:OPK)? I know there has been consistent insider buying over the years from Philip Friost, bust at some of the levels I can see (sometimes buying a few shares only) I am unsure if he is trying to pump the price amongst people watchung for ”insider […]
Frank Curzio Editor, Phase 1 Investor Yep, Frank has a closing soon pitch for a (small) oil drilling company headed (or in) Europe and ready to ride the shirt tail of a larger Oil Company to gain assess to one prescribed rich shale play in Europe. Infact, the junior exploration stock is so tiny and […]
In the last 8 months two companies have come out of the Thinkolator with a ”device” to end all disease. One company is ST Microelectronics and the other is Cyclacel Pharmaceuticals Inc. These two companies have been promoted by two different people yet with basically the same message. What did I miss or not understand? […]
[Ed note: Following is another installment from our favorite medical scribe, "Doc Gumshoe" (no, he's not a doctor). We feature Michael's commentary every couple weeks or so, and his thoughts and words are his own. "Doc" doesn't pick stocks, but who knows ... maybe you'll find yourself wanting to understand a biotech company's migraine drug […]
Does anyone have any experience with this. It is currently being teased by Agora Financial.
[ed. note: Michael Jorrin, a longtime medical writer who has earned the nickname "Doc Gumshoe" despite his lack of a stethoscope and medical diploma, is our favorite scribe on all topics health related -- we feature his columns every couple weeks here at Stock Gumshoe to help us bring some skepticism and plain speaking to […]